Process for the preparation of pyrimidinyl-4-aminopyrazole compounds
Inventors
Remarchuk, Travis • Sudhakar, Anantha
Assignees
Interested in licensing this patent?
MTEC can help explore whether this patent might be available for licensing for your application.
Abstract
The present disclosure relates to methods of making LRRK2-inhibiting, pyrimidinyl-4-aminopyrazole compounds and intermediates of formulae I and IV: The compounds are useful as LRRK2 inhibitors in the treatment of LRRK2 mediated diseases, and as intermediates for their manufacture.
Core Innovation
The disclosed subject matter includes compounds of formula V, or their salts, stereoisomers, tautomers, or deuterium analogs, with defined alternatives for X, R1, R2, R4, R5, R6, R9, and R10. The partial content also describes pyrimidinyl-4-aminopyrazole compounds and processes for preparing them through regioselective coupling and subsequent transformations; procedural details are omitted.
The formula V compounds are identified as intermediates for LRRK2 kinase inhibitors. A particular embodiment has X as chloro, R1 as methyl, R2 as trifluoromethyl, and R9 and R10 as methyl. The background section is not included in the provided partial content, so the problem addressed by the invention is not explicitly described in patent.
Claims Coverage
The provided claims identify one independent claim, claim 1, directed to a compound of formula V and specified related forms. The claim coverage is summarized in one inventive feature.
Compound of formula V with defined substituents
Claim 1 covers a compound of formula V, or a salt, stereoisomer, tautomer, or deuterium analog thereof. It defines alternatives for X, R1, R2, R4, R5, R6, R9, and R10, including specified halogen, alkyl, aryl, heteroaryl, and other substituent groups. The dependent claims narrow these alternatives to include an embodiment with X as chloro, R1, R9, and R10 as methyl, and R2 as trifluoromethyl.
The independent claim covers formula V compounds and specified related forms across defined substituent alternatives; the dependent claims include a narrower chloro, methyl, and trifluoromethyl embodiment.
Stated Advantages
The partial content reports scalable preparation of key intermediates.
Documented Applications
Formula V compounds are identified as intermediates for LRRK2 kinase inhibitors.
Interested in licensing this patent?